-+ 0.00%
-+ 0.00%
-+ 0.00%

Artelo advances ART26.12 into multiple ascending dose trial after Phase 1 safety data

PUBT·04/20/2026 11:50:18
Listen to the news
Artelo advances ART26.12 into multiple ascending dose trial after Phase 1 safety data
  • Artelo Biosciences announced peer-reviewed publication in European Journal of Pain supporting FABP5 inhibitor ART26.12 as potential first-in-class, non-opioid pain treatment.
  • Publication presented preclinical evidence showing analgesic effects across multiple pain models, positioning mechanism as differentiated alternative to opioids or NSAIDs.
  • Company reported Phase 1 single ascending dose results were already presented, citing good tolerability with no adverse events attributed to ART26.12.
  • Planned multiple ascending dose study is expected later in 2026, marking next clinical milestone for ART26.12.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200750PRIMZONEFULLFEED9692950) on April 20, 2026, and is solely responsible for the information contained therein.